Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 2

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1

Plasmids R577 and R785 decrease the resistance of Escherichia coli K12 strain W1485 to bactericidal action of normal serum

100%
Jankowski S., Cisowska A.
Journal of Applied Genetics
|
1998
|
vol. 39
|
issue 3
211-216
EN
The role of plasmids of drug resistance R577 and R785 in the development of susceptibility of Escherichia coli K12 strain W1485 to the bactericidal action of serum was studied. Plasmids R577 and R785 were transfered to cells of strain W1485 by means of conjugation. The susceptibility of cells containing the plasmid to serum was compared to that of cells lacking the plasmid. It was found that plasmids R577 and R758 sensitize bacteria to the action of serum.
2

The role of membrane glycoproteins CD46, CD55 and CD59 in protection of tumor cells against complement lysis

81%
Wojnicz D., Bar J., Jankowski S.
Postępy Higieny i Medycyny Doświadczalnej
|
2002
|
vol. 56
|
issue 5
603-616
EN
Utilization of the complement system offers potential for the elimination of tumor cells by monoclonal antibodies (mAb) immunotherapy. Activation of the complement system causes tumor cell destruction by inducing complement lysis and promoting cell ? mediated killing. In addition, complement can induce a strong inflammatory response, which might enhance other antitumor effector mechanisms. An important targets for mAb immunotherapy, however, are membrane bound complement regulatory glycoprotein: CD46, CD55 and CD59, which have been found to be expressed on most tumor cells in vivo and in vitro. Blocking or downregulation of these inhibitors could be an important step in the advancement of mAb immunotherapy.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.